Navigating New Frontiers: Bruton Tyrosine Kinase Inhibitors in Chronic Spontaneous Urticaria Treatment ...

Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients ...

The legalization of recreational marijuana in Minnesota has created daily conversations about how to incorporate the use of ...

Mirvetuximab soravtansine showed high evidence of efficacy in heavily pretreated FRα-positive, platinum-sensitive ovarian ...

Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk ...

While neoadjuvant therapy in stage III or great melanoma is already the standard of care, new research presented at ESMO ...

Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and ...

Enfortumab vedotin showed a robust disease control rate in patients with urothelial cancer outside of a clinical trial, and ...

Sheela Rao, MBBS, FRCP, MD, consultant medical oncologist at the Royal Marsden Hospital, discussed the findings of the POD1UM ...

Davey Daniel, MD, chief medical officer at OneOncology, stresses the need for real-world evidence in genomic testing to improve patient outcomes and cost-effectiveness.

Deepened, persistent responses were seen in the long term among patients with advanced melanoma treated with fianlimab and ...

Using real-world data, researchers compared 2 chimeric antigen receptor (CAR) T-cell therapies with a bispecific antibody, ...